Literature DB >> 1972164

Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients.

E A Wierenga1, M Snoek, C de Groot, I Chrétien, J D Bos, H M Jansen, M L Kapsenberg.   

Abstract

Lymphokine secretion profiles were studied of human allergen-specific CD4+ T lymphocyte clones (TLC). To this aim, panels of house dust mite Dermatophagoides pteronyssinus (Dp)-specific TLC were generated from two atopic Dp-allergic patients, suffering from severe atopic dermatitis (AD1) and allergic asthma (AD2), respectively, and from a non-atopic individual (NAD). From AD1 additional TLC were cloned specific for tetanus toxoid or Candida albicans, both Ag that were not relevant for the atopic state of this patient. Secretion of IL-2, IL-4, and IFN-gamma was determined after specific stimulation of these TLC, using autologous monocytes as APC. With respect to the production of IL-4 and IFN-gamma, clearly distinct profiles were observed. All Dp-specific TLC from both atopic donors produced IL-4 but not IFN-gamma, whereas the Dp-specific TLC from NAD, as well as the tetanus toxoid- and C. albicans-specific TLC from AD1, all produced IFN-gamma but not or small quantities of IL-4. Most TLC from all panels produced IL-2. These lymphokine profiles were consistent for at least 3 days and were neither dependent on the dose of allergen nor on the atopic or nonatopic state of the donor of APC. The functional consequence of these restricted lymphokine profiles was stressed by the observation that, whereas Dp-specific TLC from AD1 and AD2 supported in vitro IgE production, this support could be abrogated by a Dp-specific TLC from NAD. The present results suggest that CD4+ T lymphocytes that produce IL-4, but not IFN-gamma, occur in high frequencies in the allergen-specific T cell repertoires of atopic donors, which may have important implications for the pathomechanism of atopic disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  111 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Age at childhood infections and risk of atopy.

Authors:  P Bager; T Westergaard; K Rostgaard; H Hjalgrim; M Melbye
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

Review 4.  The role of allergens in the induction of asthma.

Authors:  Thomas A E Platts-Mills
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

5.  DNase I footprinting of the human interleukin-5 gene promoter.

Authors:  D J Cousins; D Richards; D M Kemeny; S Romagnani; T H Lee; D Z Staynov
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 6.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

Review 7.  T cells in allergic responses to haptens and proteins.

Authors:  M L Kapsenberg; J D Bos; E A Wierenga
Journal:  Springer Semin Immunopathol       Date:  1992

Review 8.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

9.  Imbalance of CD4+CD29+ and CD4+CD45RA+ T-helper cell subsets in peripheral blood of patients with severe atopic dermatitis.

Authors:  K Jung; A Bittrich; V Klimmek; H Schubert
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

10.  Increased adhesion of human monocytes to IL-4-stimulated human venous endothelial cells via CD11/CD18, and very late antigen-4 (VLA-4)/vascular cell adhesion molecule-1 (VCAM-1)-dependent mechanisms.

Authors:  E M Verdegaal; H Beekhuizen; I Blokland; R van Furth
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.